⚕️ Educational content only. This article explains autoimmune laboratory tests from an immunology science perspective. It is not medical advice. Consult a healthcare professional for personal health concerns.
Autoimmune diseases occur when the immune system produces antibodies directed against the body’s own tissues. Laboratory immunology tests detect these autoantibodies in blood, helping clinicians diagnose and monitor conditions such as systemic lupus erythematosus (SLE), rheumatoid arthritis, vasculitis, and autoimmune thyroid disease.
Key Takeaways
- ANA (antinuclear antibody) is a sensitive screening test for SLE and other connective tissue diseases, but is non-specific.
- Anti-dsDNA is highly specific for SLE and correlates with disease activity and lupus nephritis.
- ANCA (antineutrophil cytoplasmic antibody) is associated with vasculitides including GPA and MPA.
- Rheumatoid factor (RF) and anti-CCP are used in the diagnosis of rheumatoid arthritis; anti-CCP is more specific.
Antinuclear Antibody (ANA)
ANA testing detects antibodies directed against nuclear antigens. It is performed by indirect immunofluorescence (IIF) on HEp-2 cells, which gives a titre (e.g. 1:80, 1:160, 1:320) and a pattern (homogeneous, speckled, nucleolar, centromere). A positive ANA at a titre of ≥1:160 is considered significant. ANA is positive in >95% of SLE patients, making it a sensitive screening test, but it is also positive in other connective tissue diseases (Sjögren’s, scleroderma, myositis), and in up to 15–20% of healthy individuals at low titres. Positive ANA should trigger reflex testing for specific extractable nuclear antigens (ENAs) and anti-dsDNA.
Anti-dsDNA
Antibodies against double-stranded DNA are highly specific for SLE (>99% specificity). They are included in the ACR/EULAR classification criteria for SLE. Anti-dsDNA levels fluctuate with disease activity — rising levels often precede lupus nephritis flares, making serial monitoring clinically useful. Testing methods include Crithidia luciliae IIF (which detects high-avidity antibodies and is highly specific) and ELISA (more sensitive but less specific).
ENA Panel (Extractable Nuclear Antigens)
ENA testing detects antibodies against specific nuclear proteins. Key antigens include: anti-Ro/SSA and anti-La/SSB (Sjögren’s syndrome and neonatal lupus); anti-Sm (SLE-specific, though insensitive); anti-Scl-70 / anti-topoisomerase I (diffuse scleroderma); anti-Jo-1 (antisynthetase syndrome / inflammatory myopathy); anti-U1RNP (mixed connective tissue disease). The clinical pattern and titre guide interpretation.
ANCA (Antineutrophil Cytoplasmic Antibody)
ANCA are associated with systemic vasculitides. Two main patterns are recognised by IIF: cANCA (cytoplasmic pattern, usually directed against PR3/proteinase 3) — associated with granulomatosis with polyangiitis (GPA); and pANCA (perinuclear pattern, usually directed against MPO/myeloperoxidase) — associated with microscopic polyangiitis (MPA) and eosinophilic GPA (EGPA). ANCA results should be confirmed by PR3-ANCA and MPO-ANCA ELISA.
Rheumatoid Factor and Anti-CCP
Rheumatoid factor (RF) is an IgM antibody directed against the Fc portion of IgG. It is elevated in ~70–80% of rheumatoid arthritis (RA) patients but also in Sjögren’s, SLE, cryoglobulinaemia, and various infections, limiting its specificity. Anti-cyclic citrullinated peptide (anti-CCP) antibodies have similar sensitivity (~70%) to RF but much higher specificity (>95%) for RA. Anti-CCP can precede clinical disease by years and is used in the 2010 ACR/EULAR RA classification criteria.
References
- Aringer M, et al. 2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. Arthritis Rheumatol. 2019.
- Bossuyt X, et al. Position paper: recommendations for the laboratory detection of autoantibodies. Clin Chem Lab Med. 2017.
- NHS. Antinuclear antibody test. nhs.uk
More questions answered
Why is the autoimmune blood-test panel often interpreted with other tests?
The autoimmune blood-test panel answers one specific laboratory question, while clinical findings, inflammation markers, complement and organ-specific tests can provide different information about the same clinical problem. Looking at several results together can reveal a pattern that one value cannot show. A normal or abnormal result therefore should not be separated from the rest of the laboratory picture. This combined pattern-based interpretation is one reason clinicians often order related tests together.
Can an abnormal autoimmune blood-test panel result have more than one cause?
Yes. The autoimmune blood-test panel can be affected by background autoantibodies, age, infection, medicines and other autoimmune conditions, so an abnormal value is not specific to one condition. Different biological processes can produce similar laboratory changes even when their causes are unrelated. This is why clinical context and other test results matter before drawing conclusions. An individual abnormal result should be discussed with a healthcare professional.
Can sample quality affect the autoimmune blood-test panel?
Yes. Sample quality can influence whether the autoimmune blood-test panel is technically reliable, especially when collection, transport or processing requirements are not met. Depending on the test, problems such as haemolysis, clotting, contamination, delay or an unsuitable container may interfere with analysis. Laboratories apply specimen-acceptance rules and may add comments, repeat testing or request recollection when necessary. These checks are part of the laboratory’s quality system.
Why might the autoimmune blood-test panel be different when it is repeated?
A repeat autoimmune blood-test panel can differ because the underlying biology has changed, because of normal biological variation or because the first sample was affected by a temporary factor. Analytical systems also have small amounts of measurement variation, even when they are working correctly. Looking at a series of results helps distinguish a persistent trend from an isolated change. Clinicians therefore interpret trends over time rather than expecting every repeat value to be identical.
Does fasting or timing matter for the autoimmune blood-test panel?
Fasting or timing may matter for some laboratory requests, but it is not a universal requirement for every autoimmune blood-test panel. Preparation depends on the exact test request, so the laboratory or healthcare service should provide any fasting or timing instructions. Other tests collected at the same appointment may also determine how the blood sample should be prepared. The practical approach is to follow the laboratory’s specific collection instructions rather than using a generic fasting rule.
What does the laboratory do if a autoimmune blood-test panel result looks unexpected?
An unexpected autoimmune blood-test panel result may trigger automated rules or manual review before it is released. Laboratory staff can check the specimen, previous results, analyser flags and quality-control data to look for technical explanations. Depending on the method, the sample may be repeated, diluted, confirmed or investigated with another procedure. The goal is to make sure the reported value meets the laboratory’s validation criteria.
What are the main limitations of the autoimmune blood-test panel?
The autoimmune blood-test panel measures selected antibodies and other markers associated with autoimmune disease, but that does not mean it can explain the cause of every abnormal result. The test can support investigation of suspected autoimmune disease, yet interpretation still depends on other evidence such as related laboratory tests, clinical findings or imaging where relevant. Method limitations and biological variation can also affect the result. A useful takeaway is that the test is a piece of evidence, not a diagnosis by itself.
T Cells vs B Cells: What’s the Difference and How Are They Tested?